Small Molecule Drug Discovery Outsourcing Market Size to Surpass USD 13.43 Billion by 2034

Small Molecule Drug Discovery
Outsourcing Market Segmentation Analysis:

By Lead Identification & Candidate
Optimization Analysis:

The instruments segment dominates in the
small molecule drug discovery outsourcing market, as it helps enhance the
quality and quantity of leads, also offering greater access to professional
knowledge and skills. It cuts expenses and saves money over a period. It
increases efficiency, improves leads, provides access to commercial acumen, and
an ultimate uptick in sales. Outsourcing increases the recruitment process by
leveraging the provider’s resources and expertise to rationalize workflows.

On the other hand, the preclinical
development segment is expected to grow significantly during the forecast
period, as outsourcing pre-clinical CRO
services can lead to significant cost savings. Establishing and maintaining in-house
facilities and resources for preclinical development requires substantial
financial investment. Outsourcing preclinical studies can reduce development
timelines by up to 30% while ensuring compliance with GLP (Good Laboratory
Practice) standards.

By Service Analysis:

The chemistry services segment dominated
the market in 2024, as it improves efficiency, lowers costs, improves
compliance and safety, and provides greater expansion and sustainability
opportunities. It easily handles the storage, transportation, and delivery of
chemical products on behalf of the manufacturer.

On the other hand, the biology services
segment is expected to grow at the fastest CAGR in the market during the
forecast period, as it becomes a progressively popular approach in biotech and
pharmaceutical organizations.  Outsourcing offers access to specialized
expertise that may not be available in-house. Major contract
research organizations (CROs) employ scientists with wide experience in
biological services. As the biotech industry continues to evolve, outsourcing
is likely to play an increasingly significant role in advancing scientific
discoveries.

By Therapeutic Area Analysis:

The respiratory system segment dominated
the market in 2024, as these molecules offer advantages like huge oral
bioavailability, the capability to engage intracellular pathways, and adaptable
dosing regimens, making it applicable to a wide spectrum of respiratory
diseases

On the other hand, the oncology
segment is expected to grow at the fastest CAGR in the market during
the forecast period, as their less molecular weight, so they penetrate cell
membranes and enter cells, permitting highly personalized
interactions that directly disrupt intracellular processes in tumors. It offers
targeted therapies to cancer patients and has proven highly efficiently.

By end-use Analysis:

The pharmaceutical
& biotechnology segment dominated the market in 2024, as it
provides productivity benefits such as access to novel technology, virtualized
expenses, and risk sharing. As pharmaceutical companies face growing cost
pressures and as the difficulty of drug candidates increases, they are turning
to outsourcing partners. It lowers the requirement for cost investments and
growing access to specialized technical expertise.

On the other hand, the academic institutes
segment is expected to grow at the fastest CAGR in the market during the
forecast period, as outsourcing allows institutes to respond rapidly to
fluctuating requirements. Virtual assistants provide flexibility in managing
tasks and scale their support based on demand. This is particularly important
for institutions handling seasonal tasks, like enrollment periods or exam
preparation phases.  Institutions outsource time-consuming administrative work
to virtual assistants and free up their core team to emphasize strategic
priorities.

By Regional Insights

Which Region Dominated the Small
Molecule Drug Discovery Outsourcing Market?

North America dominated the small molecule
drug discovery outsourcing market in 2024, due to the presence largest number
of biotech companies worldwide, found in North America, which invests more than
$75 billion per year. Those investments are set to rise due to further
developments in the biotech sector, and shift from international-based to
home-grown services and manufacturing sites. Presence of major biopharma
companies such as Merck, AbbVie, Pfizer, Bristol Myers Squibb, and Johnson
& Johnson, which are major clients for outsourcing services.

United States to continue growing its
innovation economy, it should enact stronger policies that support business
R&D and federal R&D.  For instance, in 2024 U.S. will spend $193.39
billion in R&D, which will increase continuous demand for CRO and CDMO
partnerships, contributing to the growth of the market.

Why Asia Pacific is the Fastest Growing
in the Small Molecule Drug Discovery Outsourcing Market?

In Asia Pacific, major companies of this
region are increasingly opting for nearshoring, outsourcing to neighboring
countries, to decrease time zone differences, enhance communication, and take
advantage of cultural resemblances. This region is a fascinating world-renowned
organization that supports them in saving costs while delivering
advanced-quality products. Asia Pacific governments invested largely in
infrastructure to help the growing outsourcing, which contributes to the growth
of the market.

Small Molecule Drug Discovery
Outsourcing Market Companies:

• Albany Molecular Research (Curia)

• Charles
River Laboratories

• Dalton
Pharma Services

• Domainex

• Dr.
Reddy Laboratories Ltd.

• Eurofins

• Evotec

• GenScript Biotech

• Jubilant Biosys

• Laboratory Corporation of America
Holdings (Covance)

• Merck & Co., Inc.

• Oncodesign

• Pharmaceutical
Product Development, LLC

• Pharmaron

• QIAGEN

• Syngene International

• TCG Lifesciences Pvt Ltd.

• WuXi
AppTec

What is Going Around the Globe?

⬥︎ In July 2024, Innovent Biologics, Inc., a
world-class biopharmaceutical company that develops, manufactures and
commercializes high-quality medicines for the treatment of oncology,
cardiovascular and metabolic, autoimmune, ophthalmology, and other major
diseases, announced a strategic partnership with WeComput to jointly advance
the construction and improvement of Innovent Biologics’ Artificial Intelligence
for Drug Discovery platform.

⬥︎ In May 2025, Peptone announced a partnership with
Evotec to accelerate and scale the creation of small-molecule IDP-targeted
treatments across diverse therapeutic areas. Through the collaboration, Peptone
will harness Evotec’s drug discovery toolbox encompassing deep domain expertise
in oncology and immunology, extensive assay development know-how, and
state-of-the-art screening capabilities to seamlessly integrate with its
pioneering, physics-based approach to understanding IDP structural dynamics.

You can place an order or ask any
questions, please feel free to contact at [email protected]  |
+1 804 441 9344

Related Report –

⬥︎ Cell & Gene Therapy Contract Research Organizations Market –

⬥︎ Cell And Gene Therapy CDMO Market-

⬥︎ AI in Medical Imaging Market –

⬥︎ Cancer Vaccines Market –

⬥︎ Regenerative Medicine Market –

⬥︎ U.S. Large And Small-scale Bioprocessing Market –

⬥︎ Implantable Medical Devices Market –

Segments Covered in the Report

This report forecasts revenue growth at
country levels and provides an analysis of the latest industry trends in each
of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc.
has segmented the small molecule drug discovery outsourcing market.

By Workflow

• Lead Identification & Candidate
Optimization

• Target Identification & Screening

• Target Validation & Functional
Informatics

• Preclinical Development

•Others

By Service

• Biology Services

• Chemistry Services

By Therapeutic Area

• Anti-infective

• Cardiovascular

• Central Nervous System

• Dermatology

• Endocrine

• Gastrointestinal

• Genitourinary System

• Hematology

• Immunomodulation

• Oncology

• Ophthalmology

• Pain and Anesthesia

• Respiratory system

By End Use

• Academic Institutes

• Pharmaceutical & Biotechnology
companies

By Regional

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa (MEA)

Immediate Delivery Available | Buy This
Premium Research

About-Us

Nova One Advisor is a global leader
in market intelligence and strategic consulting, committed to delivering deep,
data-driven insights that power innovation and transformation across
industries. With a sharp focus on the evolving landscape of life sciences, we
specialize in navigating the complexities of cell and gene therapy, drug
development, and the oncology market, enabling our clients to lead in some of
the most revolutionary and high-impact areas of healthcare.

Our expertise spans the entire
biotech and pharmaceutical value chain, empowering startups, global
enterprises, investors, and research institutions that are pioneering the next
generation of therapies in regenerative medicine, oncology, and precision
medicine.

Web:

Contact Us

USA: +1 804 420 9370

Email: [email protected]

For Latest Update
Follow Us: LinkedIn